Decisive point for gensight in the short termSolid'action which is about to exceed probably € 10 in the short term if we go above € 9.35 at 11:45 am.
−0.5425EUR
−26.20 MEUR
3.00 MEUR
54.00 M
About GENSIGHT BIOLOGICS
Sector
CEO
Laurence Rodriguez
Headquarters
Paris
Website
Founded
2012
ISIN
FR0013183985
FIGI
BBG00D8N3240
GenSight Biologics SA is a clinical-stage gene therapy company. It is engaged in research and development of novel therapies for mitochondrial and neurodegenerative. The firm also provides ophthalmology services which develops products to restore eyesight to patients suffering from retinal diseases. The company was founded by Bernard Jacques Alex Gilly, Botond Roska, Jean Bennett, Connie Cepko, Luk H. Vandenberghe, Serge Picaud and Jose-Alain Sahel in 2012 and is headquartered in Paris, France.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SIGHT is 0.40 EUR — it has decreased by 1.00% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange GENSIGHT BIOLOGICS stocks are traded under the ticker SIGHT.
GENSIGHT BIOLOGICS is going to release the next earnings report on Sep 23, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for GENSIGHT BIOLOGICS has a max estimate of 0.40 EUR and a min estimate of 0.40 EUR.
Yes, you can track GENSIGHT BIOLOGICS financials in yearly and quarterly reports right on TradingView.
Like other stocks, SIGHT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade GENSIGHT BIOLOGICS stock right from TradingView charts — choose your broker and connect to your account.